Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Caitlin E. Cox

May 14, 2019

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Coverage and Use of Impella and Watchman: A Tale of Four Countries

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

Little Pre- and Postmarket Testing for Most Recalled CV Devices

FDA Approves Bioresorbable Scaffold for BTK Lesions

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Colchicine for Decreasing CV Events

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Expands TAVR Indication to Low-Risk Patients

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content